Candel therapeutics appoints renowned pancreatic cancer expert, elizabeth m. jaffee, m.d.

Needham, mass., march 18, 2025 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of elizabeth m. jaffee, m.d., to the company's research advisory board (rab). dr. jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the rab, which is important in light of the company's focus on borderline resectable pancreatic cancer.
CADL Ratings Summary
CADL Quant Ranking